ArticleJCI insight2020
Comprehensive plasma proteomic profiling reveals biomarkers for active tuberculosis.
Article in JCI insight, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 63 citations in OpenAlex.
- Host-pathogen interactions in tuberculosis: from immunological mechanisms to translational applications.Cell insight · 2026Review
- Systemic immune activation in hereditary cancer predisposition syndromes: a cross-sectional study.BMC medicine · 2026Article
- A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2026 Update for Clinicians and Scientists.Pathogens & immunity · 2026Review
- Preparation of the Low Molecular Weight Serum Proteome for Mass Spectrometry Analysis.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Article
- Proteomic analysis of plasma unravels dynamic pathways and potential biomarkers indicating disease stages followingmSystems · 2025Article
- A single-cell transcriptomic atlas reveals senescence and inflammation in the post-tuberculosis human lung.Nature microbiology · 2025Article
- Plasma proteomics for biomarker discovery in childhood tuberculosis.Nature communications · 2025Article
- Recent progress in tuberculosis diagnosis: insights into blood-based biomarkers and emerging technologies.Frontiers in cellular and infection microbiology · 2025Review
- Candidate serum protein biomarkers for active pulmonary tuberculosis diagnosis in tuberculosis endemic settings.BMC infectious diseases · 2024Article
- Integrated plasma proteomics identifies tuberculosis-specific diagnostic biomarkers.JCI insight · 2024Article
- Proteomic-based identification of APCS as candidate protein for diagnosis of patients exhibiting anti-tubercular drug induced liver injury.Scientific reports · 2023Article
- Network analysis of plasma proteomes in affective disorders.Translational psychiatry · 2023Article
- Commercially available CD4 + and CD8 + IFN-γ release assays combined with an HBHA-induced IGRA improve the characterization of the tuberculosis spectrum and monitoring of treatment in children.European journal of pediatrics · 2023Article
- Article
- Diagnosis and biomarkers for ocular tuberculosis: From the present into the future.Theranostics · 2023Review
- Advances in proteomics: characterization of the innate immune system after birth and during inflammation.Frontiers in immunology · 2023Review
- Development of diagnostic algorithm using machine learning for distinguishing between active tuberculosis and latent tuberculosis infection.BMC infectious diseases · 2022Article
- A protein signature associated with active tuberculosis identified by plasma profiling and network-based analysis.iScience · 2022Article
- Diagnostic biomarkers for active tuberculosis: progress and challenges.EMBO molecular medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 8 institutions in 5 countries.
Funding
Abstract
BACKGROUNDTuberculosis (TB) kills more people than any other infection, and new diagnostic tests to identify active cases are required. We aimed to discover and verify novel markers for TB in nondepleted plasma.METHODSWe applied an optimized quantitative proteomics discovery methodology based on multidimensional and orthogonal liquid chromatographic separation combined with high-resolution mass spectrometry to study nondepleted plasma of 11 patients with active TB compared with 10 healthy controls. Prioritized candidates were verified in independent UK (n = 118) and South African cohorts (n = 203).RESULTSWe generated the most comprehensive TB plasma proteome to date, profiling 5022 proteins spanning 11 orders-of-magnitude concentration range with diverse biochemical and molecular properties. We analyzed the predominantly low-molecular weight subproteome, identifying 46 proteins with significantly increased and 90 with decreased abundance (peptide FDR ≤ 1%, q ≤ 0.05). Verification was performed for novel candidate biomarkers (CFHR5, ILF2) in 2 independent cohorts. Receiver operating characteristics analyses using a 5-protein panel (CFHR5, LRG1, CRP, LBP, and SAA1) exhibited discriminatory power in distinguishing TB from other respiratory diseases (AUC = 0.81).CONCLUSIONWe report the most comprehensive TB plasma proteome to date, identifying novel markers with verification in 2 independent cohorts, leading to a 5-protein biosignature with potential to improve TB diagnosis. With further development, these biomarkers have potential as a diagnostic triage test.FUNDINGColciencias, Medical Research Council, Innovate UK, NIHR, Academy of Medical Sciences, Program for Advanced Research Capacities for AIDS, Wellcome Centre for Infectious Diseases Research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.